Taken together, targeting cancer metabolism in NSCLC has become a well-established concept [54], especially in targeting GLUT1, which facilitates glycolysis and promotes NSCLC via integrin β1/Src/FAK signaling [55]. The gene discussed is SLC2A1; the disease is non-small cell lung carcinoma.